DAFTAR PUSTAKA
1. Crocker I (2007) Pre-Eclampsia and Villous Trophoblast Turnover: Perspectives and Possibilities. Placenta.21,pp,4-13.
2. Cunningham FG, McDonal PC, Gant NF, Levano KJ, Gilstrap LC, Hankins GDV (2010) William Obstetrics, 23rd edition.
3. Heazell AE, Crocker IP (2008) Live and let die - regulation of villous trophoblast apoptosis in normal and abnormal pregnancies. Placenta 29(9):772–783.
4. Shawn L, Straszewski-Chavez, Vikki M, Abrahams, Gil Mor (2005) The Role of Apoptosis in the Regulation of Trophoblast Survival and Differentiation during Pregnancy. Endocrine Reviews 26(7):877–897. 5. Ashe PC, Berry MD (2003) Apoptotic Signaling Cascades. Progress in
Neuro-Psychopharmacology & Biological Psychiatry,27,pp.199-214. 6. Jeschke U et al ( 2006) Expression of the proliferation marker Ki-67
and of p53 tumor protein in trophoblastic tissue of preeclamptic, HELLP, and intrauterine growth-restricted pregnancies. Int J Gynecol Pathol 25(4):354–360.58
7. Levy R (2005) The Role of Apoptosis In Preeclampsia. IMAJ,7,pp.178-181.
8. Keman K, Presetyorini N, Langgar MJ (2009) Perbandingan ekspresi p53, Bcl-2, dan Indeks Apoptosis Trofoblas pada Preeklampsia/Eklampsia dan Kehamilan Normal. Majalah Obstetri dan Ginekologi Indonesia,33-3, pp.151-159.
10. Leif Matthiesen, Goran Berg, Jan Ernerudh, Christina Ekerfelt, Yvonne Jonsson, Surendra Sharma (2005) Immunology of Preeclampsia. Chem Immunol Allergy. Basel, Karger, vol 89, pp 49– 61.
11. Dekker GA, Sibai BM (1998) Etiology and Pathogenesis of Preeclampsia:Current Consepts. Am J Obstet Gynecol, 179, pp.1359-1375.
12. Robbert JM, Hubel CA (2009) The Two Stage Model of Preeclampsia: Variations on the theme. Placenta,23,pp.S32-S37.
13. Hladunewich M, Karumanchi SA, Lafayette R (2007) Pathophysiology of Clinical Manifestations of Preeclampsia. Clin J Am Soc Nephrol,2,pp.543-549.
14. Huppertz (2008) Placental Origins of Preeclampsia: Challenging the Current Hypothesis. Journal of AHA,5, pp.1970-975.
15. Himpunan Kedokteran Feto Maternal POGI (2005) Pedoman Pengelolaan Hipertensi Dalam Kehamilan di Indonesia, 2nd ed.
16. Sibai BM (2005) Diagnosis, Prevention, and Management of Eclampsia. Obstet Gynecol 2005;105:402–10.
17. Gewies A (2003) ApoReview - Introduction to Apoptosis: Page 1 – 26. 18. Levy R et al (2002) Trophoblast apoptosis from pregnancies
complicated by fetal growth restriction is associated with enhanced p53 expression. Am J Obstet Gynecol 186(5):1056-1061.
and Diminished by Epidermal Growth Factor. Am J Physiol Cell Physiol,278,pp.982-988.
20. C Hu SD, Smith L, Pang Y, Sadovsky DM, Nelson (2006) Enhanced Basal Apoptosis in Cultured Term Human Cytotrophoblasts is Associated with a Higher Expression and Physical Interaction of p53 and Bak. Placenta 27: 978-983.
21. Mauricio Busatto, Lucas Rosa Fraga, Juliano André Boquett, Diego Luiz Rovaris, Fernanda Sales Luiz Vianna, Lavínia Schuler Faccini, José Artur Bogo Chies1 and Priscila Vianna,Polymorphisms of the Apoptotic genes TP53 and MDM2 and Preeclampsia Development,Busatto et al., JFIV Reprod Med Genet 2014, 3:1
22. Andrew Neil Sharp, School of Biomedicine, The Role of p53 Modulation in Correcting Abberant Placental Apotosis in Pre-eclampsia and IUGR, A thesis submitted to the University of Manchester for the degree of PhD in the Faculty of Medical of Human Sciences.
23. Drakos, E., V. Atsaves, et al. (2009). "The therapeutic potential of p53 reactivation wild-type or mutated p53."(12): 2290-2299.
24. Drakos, E., A. Thomaides, et al. (2007). "Inhibition of p53-Murine Double Minute 2 Interaction by Nutlin-3A Stabilizes p53 and Induces Cell Cycle ." 13(11): 3380-3387.
26. Demir, R., U. A. Kayisli, et al. (2004). "Sequential expression of VEGF and its receptors in human placental villi during very early pregnancy: differences between placental vasculogenesis and angiogenesis." Placenta 25(6): 560-572.
27. Soleymanlou Nima, Jurisica Igor, Nevo Ori, Ietta Francesca, Zhang Xin, Zamudio Stacy, Post Martin, Caniggia Isabella, Molecular Evidence of Placental Hypoxia in Preeclampsia, The Journal of Clinical Endocrinology & Metabolism 90 (7):4299 – 4308.
28. Hladunewich Michelle, Karumanchi S A, Lafayette R, Pathophysiology of the Clinical Manifestations of Preeclampsia, Cin J Am Soc Nephrol 2 : 543 – 549, 2007. doi: 10.2215/CjN.03761106.
29. Brooks M. Preeclampsia linked to autism, developmental delay. Medscape Medical News [serial online].December 12, 2014;Accessed
December13,2014.Availableathttp://www.medscape.com/viewarticle/8
36496.
30. Walker CK, Krakowiak P, Baker A, Hansen RL, Ozonoff S, HertzPicciotto. Preeclampsia, Placental Insufficiency, and Autism Spectrum Disorder or Developmental Delay. JAMA Pediatr. Dec 8 2014;[Medline].
31. American College of Obstetricians and Gynecologists. Hypertension in pregnancy. ACOG TechnicalBulletin No. 219. Washington DC:
32. Barron WM, Heckerling P, Hibbard JU, et al. Reducing unnecessary coagulation testing in hypertensive disorders of pregnancy. Obstet Gynecol. Sep 1999;94(3):36470.[Medline].
33. Sibai BM. Magnesium sulfate prophylaxis in preeclampsia: Lessons learned from recent trials. Am J ObstetGynecol. Jun 2004;190(6):15206.[Medline].
34. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol. Jul2003;102(1):18192.[Medline]. 35. Ness RB, Roberts JM. Heterogeneous causes constituting the single
syndrome of preeclampsia: ahypothesis and its implications. Am J Obstet Gynecol. Nov 1996;175(5):136570.[Medline].
36. Vatten LJ, Skjaerven R. Is preeclampsiamore than one disease?. BJOG. Apr 2004;111(4):298302.[Medline].
37. . Villar J, Betran AP, Gulmezoglu M. Epidemiological basis for the planning of maternal health services.WHO/RHR. 2001.
38. Khedun SM, Moodley J, Naicker T, et al. Drug management of hypertensive disorders of pregnancy.Pharmacol Ther. 1997;74(2):22158.[Medline]
39. 12. Ngoc NT, Merialdi M, AbdelAleemH, Carroli G, Purwar M, Zavaleta N, et al. Causes of stillbirths andearly neonatal deaths: data from 7993 pregnancies in six developing countries. Bull World Health Organ.Sep 2006;84(9):699705.[Medline]. [Full Text].
